Researchers recently unveiled promising data on three new medications for diabetes and obesity at the American Diabetes Association’s 86th Scientific Sessions. Foundayo, an oral medication, showed superior results compared to existing treatments for type 2 diabetes, while retatrutide, a new injectable drug, demonstrated significant weight loss and improved blood sugar control in adults with obesity and type 2 diabetes. Both medications aim to provide more effective options for managing these chronic conditions.

For individuals looking to age well, these findings could lead to better management of weight and blood sugar levels, which are crucial for preventing complications associated with obesity and diabetes. The Phase 3 trials revealed that retatrutide led to an average weight loss of over 70 pounds in participants after 80 weeks, while Foundayo reduced A1C levels by up to 2.1% in combination with insulin. These results suggest that people struggling with weight and diabetes may soon have more effective tools at their disposal to enhance their health and longevity.

The research is still in the Phase 3 trial stage, meaning while the results are promising, they are not yet fully proven for widespread use. Foundayo has already shown strong results in diverse patient groups, including women at various stages of menopause, indicating its potential for broad applicability. Retatrutide is still being studied in multiple trials to confirm its efficacy and safety across various health conditions.

If you’re interested in these new medications, it’s important to consult with your healthcare provider. They can help determine if these treatments are suitable for you based on your health profile and needs. Meanwhile, maintaining a balanced diet and regular exercise remains essential for managing weight and blood sugar levels.

Source: investor.lilly.com